Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great covid 19 news on NVAX with results in July and the nanoflu for influenza in the pipeline this will rock en roll. Sanofis made with his vaccine 500 mil in 1 Quartal. Check out the last filling.
Nanoflu data ph3 was much better than the vaccine from Sanofis.
Huge market for nvax
Expecting marketcap around 4 or 5billion beginning next year
News from today
http://ir.novavax.com/news-releases/news-release-details/novavax-identifies-coronavirus-vaccine-candidate-accelerates
Great news on NVAX with results in July and the nanoflu for influenza in the pipeline this will rock en roll. Sanofis made with his vaccine 500 mil in 1 Quartal. Check out the last filling.
Nanoflu data ph3 was much better than the vaccine from Sanofis.
Huge market for nvax
Expecting marketcap around 4 or 5billion beginning next year
News from today
http://ir.novavax.com/news-releases/news-release-details/novavax-identifies-coronavirus-vaccine-candidate-accelerates
Infos about CPE
Stock is 7% of Audited Book Value of $8.13 Projected Cash Flow Per Share 2020 $ 2.62 Market Price $ .58 per share
Based upon the greatest Oil Basin in the World the Permian Basin in Texas.
Steven A Webster---Co-Founder of Carrizo
Steve Webster was appointed to the Callon Board in December 2019 in conjunction with the merger of Callon and Carrizo.
Mr Webster was a co-founder of Carrizo for which he served as a director since 1993 and as its Chairman of the Board since June 1997. Since 2016, Mr Webster has served as Managing Partner of AEC Partners, a private equity firm engaged in energy investment which was the successor to Avista Capital Partners, a private equity firm he co-founded in July 2005 and for which he served as Co-Managing Partner.
Mr Webster earned an MBA degree from Harvard Business School, where he was a Baker Scholar, and a BSIM degree and Honorary Doctorate from Purdue University.
Webster Callon Shares owned prior to purchases:
Direct 5,094,924
Wife 245,000
San Felipe Resources Company 43,750
Recent Insider purchases of Callon Shares by Webster:
February 28, 2020 200,000 Shares AT $ 2.12
March 2, 2020 50,000 Shares AT $ 2.13
March 2, 2020 250,000 Shares AT $ 2.10
March 3, 2020 100,000 Shares AT $ 2.05
March 4 , 2020 200,000 Shares AT $ 1.959
March 5, 2020 100,000 Shares AT $ 1.787
March 6, 2020 50,000 Shares AT $ 1.2995
March 6, 2020 300,000 Shares AT $ 1.4814
March 9, 2020 250,000 Shares AT $ .4236
March 10, 2020 200,000 Shares AT $ .512
March 11, 2020 300,000 Shares At $ .4793
March 12, 2020 100,000 Shares At .5161
Total 2,100,000 Shares of Callon
% Increase in Position 39%
Total $ Purchases $ 2,741,345
Average Cost per Share $ 1.31
Insider Gregory Conaway Vice President & Chief Accounting Officer Insider Purchase
Owned prior to Purchases 122,908 Callon Shares
Purchases
March 11, 2020 200,000 shares AT $ .4845 Share
March 19, 2020 100,000 shares AT $ .48 Share
Total owned 422,908 Callon shares after purchases--- Increase in Position 244%
https://finance.yahoo.com/quote/CPE/key-statistics?p=CPE
Audited Book Value $8.13 Per Share
Market Price $ $.58
% Market Price to Book 7% (this is RARE)
Projected Cash Flow 2020 = $ 2.62 Per Share (this is even more rare—selling at 18% cash flow)
Callon has ~70% of Q1 oil hedged at $55.45 and ~60% of full year oil hedged at that price.
No Long Term Debt due until late 2022---no near term maturities
MYOV lowfloat Biotechstock undervalue
check the link
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154772418
MYOV lowfloat Biotech stock with 3 x Phase3
400Million on the hands:
https://finance.yahoo.com/news/myovant-sciences-announces-closing-400-133010491.html
April
1x ph3 Topline Data
1x NDA
more coming in Q2
Inside buying:
coming from 20$
MYOV lowfloat Biotech stock with 3 x Phase3
400Million on the hands:
https://finance.yahoo.com/news/myovant-sciences-announces-closing-400-133010491.html
April
1x ph3 Topline Data
1x NDA
more coming in Q2
Inside buying:
coming from 20$
MYOV lowfloat Biotech stock with 3 x Phase3
400Million on the hands:
https://finance.yahoo.com/news/myovant-sciences-announces-closing-400-133010491.html
April
1x ph3 Topline Data
1x NDA
more coming in Q2
Inside buying:
coming from 20$
CPE oil stocks are golden now PE of 2
CPE is ready PE of 2 wow
Bought som CPE easy doubler
Good news TTOO should run big.
Checkout Sanofi net income in the last q report on the inflenca product. They generate 592M income. And nvax product from today's date is better than the drug of Sanofis. The skye is clear and good to go to new 53 week highs and more.
Than the main run will come after FDA
My Friend MCAP is only at 600M now US market is alone 2 billion worth
NVAX DD look at page 6
https://novavax.com/20200116-JPM-Presentation.pdf
2 billion market in the US and 4 billion worldwide
maketcap at the moment at 500 Million
NVAX DD look at page 6
https://novavax.com/20200116-JPM-Presentation.pdf
2 billion market in the US and 4 billion worldwide
maketcap at the moment at 500 Million
NVAX DD look at page 6
https://novavax.com/20200116-JPM-Presentation.pdf
2 billion market in the US and 4 billion worldwide
maketcap at the moment at 500 Million
NVAX PH3 Nanoflue inflenza FDA approved:
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
[GlobeNewswire]
GlobeNewswireMarch 24, 2020
Trial also achieves statistical significance in key secondary endpoints
Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
Company to host investor conference call today at 8:30 a.m. EDT
GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older. Using the Food and Drug Administration’s (FDA) criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone® Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.
NanoFlu Phase 3 Primary Objectives
The trial’s primary objectives were to demonstrate non-inferior immunogenicity of NanoFlu compared to Fluzone Quadrivalent using the day 28 ratio of geometric mean titers (GMT) and the difference in seroconversion rates (SCR), as well as the overall safety of NanoFlu. Immunogenicity was measured by hemagglutination inhibition (HAI) assays using egg-derived reagents.
NanoFlu achieved the primary endpoints, both GMT and SCR, for all four strains included in the vaccine.
NanoFlu was well-tolerated and had a safety profile comparable to Fluzone Quadrivalent with a modest increase in local adverse events (AEs).
“With these data, we now have a clear path forward to licensure with our differentiated recombinant influenza vaccine,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “These strong Phase 3 results align with and validate our previous clinical trials, in which NanoFlu showed higher HAI antibody responses than the leading flu vaccine for older adults. We expect that both Fast Track designation and the accelerated approval pathway from the FDA will help Novavax bring NanoFlu to market as quickly as possible to address the serious public health threat of influenza.”
NanoFlu Phase 3 Secondary Objectives
The trial’s key secondary endpoints assessed GMT and SCR, but with an HAI assay based on wild-type reagents, which are expected to provide a more accurate assessment of clinically relevant HAI antibody responses against circulating wild-type viruses.
NanoFlu demonstrated significantly higher GMT and SCR than Fluzone Quadrivalent across all four strains included in the vaccine.
24%-66% higher GMT responses; and
11.4-20.4 higher SCR percentage points.
NanoFlu also demonstrated significantly higher GMT and SCR than Fluzone Quadrivalent for four tested drifted H3N2 strains not included in the vaccine but circulating this year.
34%-41% higher GMT responses; and
14.1-16.8 higher SCR percentage points
“In addition to meeting the primary objectives, we are very pleased to report that NanoFlu also met or exceeded its secondary endpoints for all four strains using our proprietary HAI assay based upon wild-type reagents,” said Gregory Glenn, M.D., President of Research and Development of Novavax. “NanoFlu demonstrated significant improvement against four drifted H3N2 strains that are co-circulating this year. These data, similar to what was shown in our Phase 2 clinical trial, demonstrate that NanoFlu overcomes issues related to egg-adaptation and antigenic drift. We extend our sincere appreciation to those who volunteered for this important study and to our clinical partners who worked so quickly and diligently on this trial.”
Webcast Conference Call
Novavax will host a webcast/conference call today at 8:30 a.m. ET. The webcast can be accessed via a link on the home page of the Novavax website (novavax.com) or through the “Investor Info”/“Events” tab on the Novavax website. Listeners who wish to ask questions or don’t have internet access can dial-in to the conference call at (877) 212-6076 (domestic) or (707) 287-9331 (international) and use passcode 4498251.
A replay of the webcast will be available on the Novavax website until June 24, 2020 and a replay of the conference call only will be available starting at 11:30 a.m. ET on March 24, 2020 until 11:30 a.m. ET on March 31, 2020. To access the conference call replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use passcode 4498251.
About Phase 3 Clinical Trial
The trial enrolled 2,652 healthy older adults across 19 U.S. clinical sites. Trial participants received either NanoFlu or the comparator, both of which were formulated with the four influenza strains recommended for the 2019-2020 Northern hemisphere influenza season. Participants will be followed for approximately one year after injection, with primary immunogenicity analyses of the Day 28 sera samples.
About NanoFlu™ and Matrix-M™
NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. The qNIV vaccine antigens were derived from A/Brisbane 02/2018 H1N1, A/Kansas 14/2017 H3N2, B/Maryland 15/2016 and B/Phuket 3073/2013. NanoFlu contains Novavax’ patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes.
NVAX PH3 Nanoflue inflenza FDA approved:
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
[GlobeNewswire]
GlobeNewswireMarch 24, 2020
Trial also achieves statistical significance in key secondary endpoints
Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
Company to host investor conference call today at 8:30 a.m. EDT
GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older. Using the Food and Drug Administration’s (FDA) criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone® Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.
NanoFlu Phase 3 Primary Objectives
The trial’s primary objectives were to demonstrate non-inferior immunogenicity of NanoFlu compared to Fluzone Quadrivalent using the day 28 ratio of geometric mean titers (GMT) and the difference in seroconversion rates (SCR), as well as the overall safety of NanoFlu. Immunogenicity was measured by hemagglutination inhibition (HAI) assays using egg-derived reagents.
NanoFlu achieved the primary endpoints, both GMT and SCR, for all four strains included in the vaccine.
NanoFlu was well-tolerated and had a safety profile comparable to Fluzone Quadrivalent with a modest increase in local adverse events (AEs).
“With these data, we now have a clear path forward to licensure with our differentiated recombinant influenza vaccine,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “These strong Phase 3 results align with and validate our previous clinical trials, in which NanoFlu showed higher HAI antibody responses than the leading flu vaccine for older adults. We expect that both Fast Track designation and the accelerated approval pathway from the FDA will help Novavax bring NanoFlu to market as quickly as possible to address the serious public health threat of influenza.”
NanoFlu Phase 3 Secondary Objectives
The trial’s key secondary endpoints assessed GMT and SCR, but with an HAI assay based on wild-type reagents, which are expected to provide a more accurate assessment of clinically relevant HAI antibody responses against circulating wild-type viruses.
NanoFlu demonstrated significantly higher GMT and SCR than Fluzone Quadrivalent across all four strains included in the vaccine.
24%-66% higher GMT responses; and
11.4-20.4 higher SCR percentage points.
NanoFlu also demonstrated significantly higher GMT and SCR than Fluzone Quadrivalent for four tested drifted H3N2 strains not included in the vaccine but circulating this year.
34%-41% higher GMT responses; and
14.1-16.8 higher SCR percentage points
“In addition to meeting the primary objectives, we are very pleased to report that NanoFlu also met or exceeded its secondary endpoints for all four strains using our proprietary HAI assay based upon wild-type reagents,” said Gregory Glenn, M.D., President of Research and Development of Novavax. “NanoFlu demonstrated significant improvement against four drifted H3N2 strains that are co-circulating this year. These data, similar to what was shown in our Phase 2 clinical trial, demonstrate that NanoFlu overcomes issues related to egg-adaptation and antigenic drift. We extend our sincere appreciation to those who volunteered for this important study and to our clinical partners who worked so quickly and diligently on this trial.”
Webcast Conference Call
Novavax will host a webcast/conference call today at 8:30 a.m. ET. The webcast can be accessed via a link on the home page of the Novavax website (novavax.com) or through the “Investor Info”/“Events” tab on the Novavax website. Listeners who wish to ask questions or don’t have internet access can dial-in to the conference call at (877) 212-6076 (domestic) or (707) 287-9331 (international) and use passcode 4498251.
A replay of the webcast will be available on the Novavax website until June 24, 2020 and a replay of the conference call only will be available starting at 11:30 a.m. ET on March 24, 2020 until 11:30 a.m. ET on March 31, 2020. To access the conference call replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use passcode 4498251.
About Phase 3 Clinical Trial
The trial enrolled 2,652 healthy older adults across 19 U.S. clinical sites. Trial participants received either NanoFlu or the comparator, both of which were formulated with the four influenza strains recommended for the 2019-2020 Northern hemisphere influenza season. Participants will be followed for approximately one year after injection, with primary immunogenicity analyses of the Day 28 sera samples.
About NanoFlu™ and Matrix-M™
NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. The qNIV vaccine antigens were derived from A/Brisbane 02/2018 H1N1, A/Kansas 14/2017 H3N2, B/Maryland 15/2016 and B/Phuket 3073/2013. NanoFlu contains Novavax’ patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes.
NVAX PH3 Nanoflue inflenza FDA approved:
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
[GlobeNewswire]
GlobeNewswireMarch 24, 2020
Trial also achieves statistical significance in key secondary endpoints
Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
Company to host investor conference call today at 8:30 a.m. EDT
GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older. Using the Food and Drug Administration’s (FDA) criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone® Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.
NanoFlu Phase 3 Primary Objectives
The trial’s primary objectives were to demonstrate non-inferior immunogenicity of NanoFlu compared to Fluzone Quadrivalent using the day 28 ratio of geometric mean titers (GMT) and the difference in seroconversion rates (SCR), as well as the overall safety of NanoFlu. Immunogenicity was measured by hemagglutination inhibition (HAI) assays using egg-derived reagents.
NanoFlu achieved the primary endpoints, both GMT and SCR, for all four strains included in the vaccine.
NanoFlu was well-tolerated and had a safety profile comparable to Fluzone Quadrivalent with a modest increase in local adverse events (AEs).
“With these data, we now have a clear path forward to licensure with our differentiated recombinant influenza vaccine,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “These strong Phase 3 results align with and validate our previous clinical trials, in which NanoFlu showed higher HAI antibody responses than the leading flu vaccine for older adults. We expect that both Fast Track designation and the accelerated approval pathway from the FDA will help Novavax bring NanoFlu to market as quickly as possible to address the serious public health threat of influenza.”
NanoFlu Phase 3 Secondary Objectives
The trial’s key secondary endpoints assessed GMT and SCR, but with an HAI assay based on wild-type reagents, which are expected to provide a more accurate assessment of clinically relevant HAI antibody responses against circulating wild-type viruses.
NanoFlu demonstrated significantly higher GMT and SCR than Fluzone Quadrivalent across all four strains included in the vaccine.
24%-66% higher GMT responses; and
11.4-20.4 higher SCR percentage points.
NanoFlu also demonstrated significantly higher GMT and SCR than Fluzone Quadrivalent for four tested drifted H3N2 strains not included in the vaccine but circulating this year.
34%-41% higher GMT responses; and
14.1-16.8 higher SCR percentage points
“In addition to meeting the primary objectives, we are very pleased to report that NanoFlu also met or exceeded its secondary endpoints for all four strains using our proprietary HAI assay based upon wild-type reagents,” said Gregory Glenn, M.D., President of Research and Development of Novavax. “NanoFlu demonstrated significant improvement against four drifted H3N2 strains that are co-circulating this year. These data, similar to what was shown in our Phase 2 clinical trial, demonstrate that NanoFlu overcomes issues related to egg-adaptation and antigenic drift. We extend our sincere appreciation to those who volunteered for this important study and to our clinical partners who worked so quickly and diligently on this trial.”
Webcast Conference Call
Novavax will host a webcast/conference call today at 8:30 a.m. ET. The webcast can be accessed via a link on the home page of the Novavax website (novavax.com) or through the “Investor Info”/“Events” tab on the Novavax website. Listeners who wish to ask questions or don’t have internet access can dial-in to the conference call at (877) 212-6076 (domestic) or (707) 287-9331 (international) and use passcode 4498251.
A replay of the webcast will be available on the Novavax website until June 24, 2020 and a replay of the conference call only will be available starting at 11:30 a.m. ET on March 24, 2020 until 11:30 a.m. ET on March 31, 2020. To access the conference call replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use passcode 4498251.
About Phase 3 Clinical Trial
The trial enrolled 2,652 healthy older adults across 19 U.S. clinical sites. Trial participants received either NanoFlu or the comparator, both of which were formulated with the four influenza strains recommended for the 2019-2020 Northern hemisphere influenza season. Participants will be followed for approximately one year after injection, with primary immunogenicity analyses of the Day 28 sera samples.
About NanoFlu™ and Matrix-M™
NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. The qNIV vaccine antigens were derived from A/Brisbane 02/2018 H1N1, A/Kansas 14/2017 H3N2, B/Maryland 15/2016 and B/Phuket 3073/2013. NanoFlu contains Novavax’ patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes.
CLSN trading under the offering price.
Interesting ist That the offering price is the same like the Lows in Nov.
Now they have enough money for they ph3 drug. News will come out 1 half of year.
Also interesting 4 insider market buys before the offering
CLSN trading under the offering price.
Interesting ist That the offering price is the same like the Lows in Nov.
Now they have enough money for they ph3 drug. News will come out 1 half of year.
Also interesting 4 insider market buys before the offering
CLSN trading under the offering price.
Interesting ist That the offering price is the same like the Lows in Nov.
Now they have enough money for they ph3 drug. News will come out 1 half of year.
Also interesting 4 insider market buys before the offering
TNXP nice close
NVAX and next month is phase 3 fda decision.
Yes big runner today,
NVAX still doing good soon we will se double digits
Stocktwets than here
TNXP news
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
This lowfloater Will fly over 2$
http://www.globenewswire.com/news-release/2020/01/24/1974846/0/en/Tonix-Pharmaceuticals-Announces-Successful-Completion-of-a-Fed-Fasting-and-Dose-Proportionality-Study-of-TNX-102-SL.html
TNXP news
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
This lowfloater Will fly over 2$
http://www.globenewswire.com/news-release/2020/01/24/1974846/0/en/Tonix-Pharmaceuticals-Announces-Successful-Completion-of-a-Fed-Fasting-and-Dose-Proportionality-Study-of-TNX-102-SL.html
TNXP news
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
This lowfloater Will fly over 2$
http://www.globenewswire.com/news-release/2020/01/24/1974846/0/en/Tonix-Pharmaceuticals-Announces-Successful-Completion-of-a-Fed-Fasting-and-Dose-Proportionality-Study-of-TNX-102-SL.html
TTOO near 1.23 breakout point. Close over 1.25 will be perfect. First target 1.50 than 1.75
TTOO near 1.23 breakout point. Close over 1.25 will be perfect. First target 1.50 than 1.75
TTOO near 1.23 breakout point. Close over 1.25 will be perfect. First target 1.50 than 1.75
Wait and see
NVAX eyes on it. With the bird flue news from Germany and czech
And some similar virus like Sars in China.
NVAX have the drugs to deliver or there are in ph3 stage to bring it soon to the market.
Double digits soon.
NVAX eyes on it. With the bird flue news from Germany and czech
And some similar virus like Sars in China.
NVAX have the drugs to deliver or there are in ph3 stage to bring it soon to the market.
Double digits soon.
At the moment we still have a low floater. The pre market is not the same as it will start. Could be that the trader jump out. But if we got some good news than it will run again very fast.
I'm still in. They have a filling you can post the filling here?
NVAX today the bird flu arrived in Germany and Tschechien big headline. This should give nvax extra fuel for double digits.
NVAX today the bird flu arrived in Germany and Tschechien big headline. This should give nvax extra fuel for double digits.